Jacob McKell's CV - Publications and Poster Conferences

Co-authored Publications

BEEHIVE Study Vaccine Effectiveness Protocol

Yoon, S. K. et al, (2026). Real-World Effectiveness and Noninferiority Evaluation and Comparison of Messenger RNA-Based and Protein-Based COVID-19 Vaccines: Protocol for the BEEHIVE Randomized Study With a Hybrid Effectiveness Design. JMIR research protocols, 15, e80858. url: https://doi.org/10.2196/80858.

SHIELD Vaccine Reactogenicity Study

Sarang K Yoon et al, mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and Their Relationship to Productivity for Healthcare Workers and First Responders, Open Forum Infectious Diseases, Volume 13, Issue 4, April 2026, ofag141, url: https://doi.org/10.1093/ofid/ofag141

PROTECT Pediatric Cohort Study Vaccine Intentions

K., Lutrick et al. (Sept. 2022). “Parental intentions and perceptions toward COVID-19 vaccination among children aged 4 months to 4 years—PROTECT cohort, four states, July 2021-May 2022.” In: Morbidity and Mortality Weekly Report 71(35).18, pp. 1119–1124. url: https://doi.org/10.15585/mmwr.mm7135a2.

Tight Junction Regulation

C., Mendoza et al. (Dec. 2019). “Calcium regulates the interplay between the tight junction and epithelial adherens junction at the plasma membrane.” In: FEBS Letters 596(2).18, pp. 219–231. url: https://doi.org/10.1002/1873-3468.14252.

Presentations

“Incidence of COVID-19 infection in Utah children during delta and omicron circulation.”

J, McKell, Langston M, et al. (Apr. 2022).
21st Annual Regional National Occupational Research Agenda (NORA) Young/New Investigators Symposium, University of Utah, Salt Lake City, UT, USA.
5th Annual Education, Research, Community Engagement Poster Summit, University of Utah, Salt Lake City, UT, USA | Poster presentation.

“Demographic Factors and Symptoms Associated with Long-COVID in Non-hospitalized Children and Youth in the Utah PROTECT Cohort.”

J, McKell, Griffin J, et al. (Apr. 2023).
22nd Annual Regional National Occupational Research Agenda (NORA) Young/New Investigators Symposium, University of Utah, Salt Lake City, UT, USA.
Awarded BLOHSWEIC award for “Best Poster”
6th Annual Education, Research, Community Engagement Poster Summit, University of Utah, Salt Lake City, UT, USA

BEEHIVE Study Reactogenicity: IDweek 2025

"Difference in Reactogenicity Events Between mRNA and Protein-subunit Vaccines: Results from the Booster Epidemiological Evaluation of Health, Illness, and Vaccine Efficacy (BEEHIVE) Study, a U.S. randomized trial of 2023-2024 COVID-19 vaccines (XBB.1.5)"
Sarang K. Yoon, Matthew S. Thiese, et al. (Oct. 2025).
Presented at ID week 2025 in Atlanta, Georgia, USA

Busy as a Bee: The Team Driving the Hive in the BEEHIVE Study

Sarang K. Yoon et al.
Methods and study procedures presented to a group of physician researchers
Presented at "Clinical Research and Methods," a monthly program by the University of Utah's Clinical and Translational Science Institute

Acknowledged Contributions

Pediatric Vaccine Effectiveness 2021-22

L., Fowlkes A. et al. (Dec. 2022). “Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022”. In: MMWR: Morbidity and mortality weekly report 71(11), pp. 422–428. url: https://doi.org/10.15585/mmwr.mm7111e1.

Effects of PFAS on Pediatric Serum Antibodies

J., Hollister et al. (Dec. 2023). “Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies.” In: Environmental research 239(Pt 1), p. 117297. url: https://doi.org/10.1016/j.envres.2023.117297.

Pediatric Vaccine Effectiveness 2021-23

R., Feldstein L., Britton A., et al. (Dec. 2023). “Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.” In: JAMA 331(5), pp. 408–416. url: https://doi.org/10.1001/jama.2023.27022.

Hybrid Immunity in Adult Front-line Workers

K., Romine J. et al. (Dec. 2024). “Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study”. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 79(1), pp. 96-107. url: https://doi.org/10.1093/cid/ciae130.

RAIVEN Double-Blind Influenza Vaccine Trial

L., Grant et al. (Sept. 2024). “Relative effectiveness and immunogenicity of quadrivalent recombinant influenzavaccine versus egg-based inactivated influenza vaccine among adults aged 18-64 years: Results and experiencefrom a randomized, double-blind trial.” In: Open Forum Infectious Diseases 10(2). url: https://doi.org/10.1093/ofid/ofae559.

Front-line Workers and SARS-CoV-2 Immunity

Hollister, J. et al. (2024). Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PloS one, 19(12), e0306953. https://doi.org/10.1371/journal.pone.0306953.

Pediatric Illness Outcomes

Porter, C. et al. (2024). Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort. Diseases, 12(8), 171. https://doi.org/10.3390/diseases12080171.

Long-COVID in Adult Front-line Workers

J., Mak et al. (Dec. 2025). “Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers”. In: The Journal of infectious diseases 231(3), pp. 665–676. url: https://doi.org/10.1093/infdis/jiae556.

Pediatric Immunity to COVID-19: Ages 6 Months to 4 Years

R., Feldstein L., Ruffin J., et al. (Dec. 2025). “Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023”. In: Journal of the Pediatric Infectious Diseases Society 14(1), piae121. url: https://doi.org/10.1093/jpids/piae121.

Pediatric Long-COVID: Ages 5 to 17 Years

R., Yousaf A. et al. (Dec. 2025). “COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years”. In: JAMA network open 8(2), e2459672. url: https://doi.org/10.1001/jamanetworkopen.2024.59672.

Jacob McKell, BS

Co-authored Publications

Presentations

Acknowledged Contributions